Martingale Asset Management L P cut its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 64.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,406 shares of the biopharmaceutical company’s stock after selling 13,205 shares during the quarter. Martingale Asset Management L P’s holdings in Emergent Biosolutions were worth $374,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Stratos Wealth Partners LTD. purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $134,000. PNC Financial Services Group Inc. increased its position in shares of Emergent Biosolutions by 108.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,482 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $171,000. Financial Gravity Wealth Inc. purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $190,000. Finally, Sei Investments Co. increased its position in shares of Emergent Biosolutions by 5,992.1% during the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares during the last quarter. 83.01% of the stock is owned by hedge funds and other institutional investors.
In related news, Chairman Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, July 12th. The stock was sold at an average price of $54.50, for a total value of $817,500.00. Following the completion of the sale, the chairman now owns 1,527,593 shares of the company’s stock, valued at approximately $83,253,818.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director George A. Joulwan sold 5,000 shares of Emergent Biosolutions stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $52.89, for a total value of $264,450.00. Following the completion of the sale, the director now directly owns 30,272 shares of the company’s stock, valued at approximately $1,601,086.08. The disclosure for this sale can be found here. In the last three months, insiders sold 79,311 shares of company stock valued at $4,398,920. 16.50% of the stock is currently owned by insiders.
EBS has been the subject of several research analyst reports. Wells Fargo & Co set a $61.00 target price on Emergent Biosolutions and gave the company a “hold” rating in a research report on Friday, August 10th. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Monday, August 20th. Cantor Fitzgerald initiated coverage on Emergent Biosolutions in a research report on Monday, June 11th. They set a “buy” rating and a $62.00 target price for the company. Cowen reaffirmed a “hold” rating and set a $49.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, August 29th. Finally, Chardan Capital raised their target price on Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $59.88.
Shares of EBS opened at $59.78 on Thursday. Emergent Biosolutions Inc has a fifty-two week low of $35.64 and a fifty-two week high of $64.00. The stock has a market capitalization of $3.10 billion, a P/E ratio of 24.70, a PEG ratio of 1.31 and a beta of 1.25. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. During the same quarter last year, the firm posted $0.13 EPS. The firm’s revenue for the quarter was up 118.5% on a year-over-year basis. sell-side analysts expect that Emergent Biosolutions Inc will post 2.37 earnings per share for the current year.
Emergent Biosolutions Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Recommended Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.